Ratings Oscar Health, Inc.

Equities

OSCR

US6877931096

Real-time Estimate Cboe BZX Other stock markets 02:05:53 2024-05-17 pm EDT			5-day change	1st Jan Change
22.44 ^USD	+1.33%		+3.97%	+145.90%

May. 15	Transcript : Oscar Health, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:40 AM
May. 09	Goldman Sachs Adjusts Price Target on Oscar Health to $21 From $16, Maintains Neutral Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
The company is in a robust financial situation considering its net cash and margin position.
The stock, which is currently worth 2024 to 0.37 times its sales, is clearly overvalued in comparison with peers.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 302.06 times its estimated earnings per share for the ongoing year.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Life & Health Insurance

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OSCAR HEALTH, INC.	+142.08%	5.25B		-
BUPA ARABIA FOR COOPERATIVE INSURANCE COMPANY	+14.06%	9.72B		B-
MEDIBANK PRIVATE LIMITED	+1.97%	6.82B		C+
THE COMPANY FOR COOPERATIVE INSURANCE	+8.91%	5.67B		C
TRUPANION, INC.	+7.57%	1.38B		C
RELIGARE ENTERPRISES LIMITED	+1.59%	866M	-	D+
THE MEDITERRANEAN AND GULF COOPERATIVE INSURANCE AND REINSURANCE COMPANY	+70.28%	686M	-	C
AMANA COOPERATIVE INSURANCE COMPANY	-0.76%	149M	-	-
PT LIPPO GENERAL INSURANCE TBK	-18.52%	62.19M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes